The failed trial studied Wainua in transthyretin amyloid cardiomyopathy or ATTR-CM. ・Jefferies said in a note that the data ...

On August 20, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced that it will present new cardiometabolic data for TRYNGOLZA (olezarsen) and its investigational siRNA ION775 at the European Society ...

It has been about a month since the last earnings report for Ionis Pharmaceuticals (IONS). Shares have added about 17.2% in that time frame, outperforming the S&P 500. But investors have to be ...

AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

A drug that didn't meet expectations in a trial is to blame.

We sat down with CEO Brett Monia to talk through 2026 and beyond -- and why Ionis is thinking well past its near-term ...

Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news ...

- Positive data from a Phase 2 study of IONIS-FB-L Rx support further development for treatment of patients with IgA nephropathy CARLSBAD, Calif., July 11, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, ...

CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license ...

FDA grants priority review to Jemperli after a trial shows yearlong disappearance of rectal tumors. The decision from the U.S. Court of Appeals for the Fifth Circuit rejected a lawsuit brought by the ...